Nadir Ahmad

Mr. Nadir Ahmad


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Healthcraft Frontiers
Verified
Journal Article
Open access
HAHamad Ali
Hamad Ali
EAEbad Ali
Ebad Ali
QAQaisar Ali
Qaisar Ali
Nadir AhmadNadir Ahmad
Nadir Ahmad
HKHammad Khan
Hammad Khan
IKIdrees Khan
Idrees Khan
Metformin remains the cornerstone of pharmacological management for Type 2 diabetes mellitus (T2DM); however, its long-term use has been associated with impaired vitamin B12 absorption and macrocytosis. The prevalence and independent determinants of macrocytosis in metformin-treated populations remain insufficiently characterized. A cross-sectional observational study was conducted at Saidu Teaching Hospital, Swat, between July 2024 and August 2025. A total of 236 adults with T2DM receiving metformin therapy for at least six months were enrolled. Macrocytosis was defined as a mean corpuscular volume (MCV) exceeding 100 fL. Demographic characteristics, clinical parameters, and concomitant medication use were systematically recorded. Univariate analyses were initially performed, followed by multivariate logistic regression to identify independent predictors of macrocytosis. The overall prevalence of macrocytosis was 16.1% (95% confidence interval (CI): 11.7-21.4%). Multivariate analysis demonstrated that metformin therapy duration >4 years (odds ratio (OR): 3.42, p = 0.002), daily metformin dose ≥1500 mg (OR: 2.89, p = 0.006), concomitant proton pump inhibitor (PPI) use (OR: 4.15, p < 0.001), and age ≥60 years (OR: 2.26, p = 0.030) were independently associated with macrocytosis, with concurrent PPI use emerging as the strongest predictor. These findings indicate that macrocytosis is a relatively common hematologic abnormality in metformin-treated adults with T2DM and is strongly influenced by treatment duration, dosage intensity, age, and concurrent PPI therapy. Risk-stratified surveillance strategies incorporating periodic assessment of MCV and serum vitamin B12 levels may therefore be warranted, particularly in high-risk patients, to enhance patient safety and optimize the long-term clinical management of T2DM.

10 February 2025 in Futurity Medicine
Verified
Journal Article
Open access
PDF file
HAHamad Ali
Hamad Ali
MRMuhammad Rizwan
Muhammad Rizwan
QAQaisar Ali
Qaisar Ali
AAArif Ali
Arif Ali
IUInam Ullah
Inam Ullah
Nadir AhmadNadir Ahmad
Nadir Ahmad
Aims: The research aims to determine quantitative values of HBeAg and HBeAb concentrations in chronic hepatitis B patients while assessing their relationship with serum hepatitis B DNA levels. Place and Duration of Study: This study was conducted at Saidu Teaching Hospital, Swat. This study lasts for 6 months, from December 2023 to April 2024. Methodology: This study comprised 100 patients with confirmed HBV DNA positive and a chronic hepatitis B. Exclusion criteria included those using antiviral medication, those with autoimmune or metabolic liver disorders, and those with co-infections (HCV, HIV, or HDV). HBeAg and HBeAb levels were assessed using CLIA, and HBV DNA was processed using qRT-PCR. Accuracy was ensured using internal quality control measures. To evaluate the correlations between HBV DNA, HBeAg, and HBeAb, data analysis was done using SPSS Version 17.0 and Pearson correlation. P-values less than 0.05 were regarded as statistically significant. Results: The mean viral load of the 100 patients was 60,800 IU/mL, and all of them tested positive for HBV DNA. HBeAb was 8.75 IU/mL on average, while HBeAg was 12.82 IU/mL on average. HBV DNA and HBeAg were found to be 59% associated, HBV DNA and HBeAb to be 46%, and HBeAg and HBeAb to be 77%, according to the correlation study. Epidemiological insights into the distribution and correlation of HBV markers in chronic hepatitis B patients are provided by these findings. Conclusion: This study concluded that not all chronic HBV patients have HBeAg and HBeAb levels, which are lower than those of HBV DNA. These findings offer valuable information on the serological trends of chronic hepatitis B, which might aid in comprehending how the illness develops.

30 December 2023 in National Journal of Life and Health Sciences
Verified
Journal Article
Open access
PDF file
Nadir AhmadNadir Ahmad
Nadir Ahmad
MSMuhammad Sanab
Muhammad Sanab
FIFawad Inayat
Fawad Inayat
ZSZar Shad
Zar Shad
MAMussadiq Ahmad
Mussadiq Ahmad
Background: Typhoid fever, caused by Salmonella typhi, has become a major public health problem worldwide, particularly in developing nations like Pakistan, as a result of the emergence of resistant strains. The aim of this study was to identify unique differences in antibiotic susceptibility across Salmonella typhi isolates isolated from human blood samples, providing insight into critical patterns impacting successful treatment approaches. Methodology: 2000 patients’ blood samples collect whose sign and symptom like typhoid positive individuals were cultured on blood agar and MacConkey agar to detect Salmonella typhi. Biochemical assays were used to identify the bacterium, and the disc diffusion method on MHA agar was used to evaluate its susceptibility to eleven antibiotics. Results: Salmonella typhi (5%) was identified from patients' blood samples. Ciprofloxacin resistance was found in 32% of those tested, followed by resistance to azithromycin (41%), ceftazidime (87%), cefotaxime (88%), sulactum/cefoperazone and piperacillin/tazobactam (89%), and chloramphenicol (97%) and Tigecycline, Imipenem, Gentamicin and Amikacin along with Meropenem shows 0% resistance toward bacterium otherwise there was no Funding. Conclusion: According to our findings, Salmonella typhi very rapidly developing resistance to antimicrobial drugs as a result of virulence transfer and antibiotic resistance, this might lead to treatment failure in typhoid patients in Pakistan.